Abstract
The TRAILR1/TRAIL system is implicated in the induction of the extrinsic apoptotic pathway and constitutes an emerging target in cancer therapeutics. The objective of this study is to assess lymphoma risk associated with certain polymorphisms in TRAILR1 and TRAIL1 genes. DNA was extracted from 381 subjects (190 lymphoma cases and 191 matched controls) and genotyped for polymorphisms rs20576, rs2230229 and rs20575 in TRAILR1 and rs12488654 in TRAIL gene. In contrast to TRAILR1 polymorphisms, the genotype distribution of rs12488654 in TRAIL gene was different between cases and controls, A allele carriers (CA/AA) being much more common in the cases with different lymphoma types (follicular, 45 %; diffuse large B cell, 45.2 % and Hodgkin lymphomas, 40 %) than in controls (15.7 %) (odds ratio (OR), 3.5; CI, 2.1–5.9; p < 0.001; OR, 3.5; CI, 1.6–7.9; p = 0.001; OR, 2.9; CI, 1.1–7.5; p = 0.027, respectively). This effect was consistently independent of the association with the TRAILR1 polymorphisms studied, as demonstrated by linkage disequilibrium and haplotype analyses. This study is the first one to report an association between a TRAIL polymorphism and lymphoma risk and suggests a possible role of TRAIL in B cell lymphomagenesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Frank B, Shanmugam KS, Beckmann L, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B (2006) Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 15:2002–2005
Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X (2003) Death receptor 4 and bladder cancer risk. Cancer Res 63:1157–1159
Langsenlehner T, Langsenlehner U, Renner W, Kapp KS, Krippl P, Hofmann G, Clar H, Pummer K, Mayer R (2008) The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate 68:264–268
Chen B, Liu S, Wang XLXW, Li Y, Zhao WH, Wu JQ (2009) TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur J Cancer 45:2598–2605
Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Gröne HJ, Hofele C, Hemminki K, Kumar R, Steineck G, Döhner H, Stilgenbauer S, Lichter P (2006) Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 118:1831–1835
Fernandez V, Jares P, Bea S, Salaverria I, Guino E, de Sanjosé S, Colomer D, Ott G, Montserrat E, Campo E (2004) Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica 89:1322–1331
Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Kang CS, Kim KM, Jang JJ, Nam SW, Lee JY, Yoo NJ (2001) Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 20:399–403
Pal R, Gochhait S, Chattopadhyay S, Gupta P, Prakash N, Agarwal G, Chaturvedi A, Husain N, Husain SA, Bamezai RN (2011) Functional implication of TRAIL −716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treat 126:333–343
Ruiz-Cosano J, Conesa-Zamora P, González-Conejero R, Pérez-Ceballos E, Martínez-Francés A, Vicente V, Pérez-Guillermo M (2012) Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: influence of geographical factors and occupational exposure. Mol Carcinog 51:508–513
Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P (2012) Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 79:591–596
Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis. Cell Res 19:519–23. http://analysis2.bio-x.cn/myAnalysis.php. Accessed 12 Jan 2013
Mitelman F, Mertens F, Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15:417–474
Monni O, Joensuu H, Franssila K, Knuutila S (1996) DNA copy number changes in diffuse large B-cell lymphoma—comparative genomic hybridization study. Blood 87:5269–5278
Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR (2009) Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol 146:418–423
Nogai H, Dörken B, Lenz G (2011) Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 29:1803–1811
Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS (2007) Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13:4556–4564
Kodadek T (2010) Development of antibody surrogates for the treatment of cancers and autoimmune disease. Curr Opin Chem Biol 14:721–727
Acknowledgments
We are very grateful to Diego Arcas for reviewing the English version of the manuscript. This work was funded by CajaMurcia Foundation (project reference: CM/12/08), Murcia, Spain.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heredia-Galvez, B., Ruiz-Cosano, J., Torres-Moreno, D. et al. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Ann Hematol 93, 243–247 (2014). https://doi.org/10.1007/s00277-013-1864-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-013-1864-4